Premium
Mucormycete infection or colonisation: experience of an Australian tertiary referral centre
Author(s) -
Langford S.,
Trubiano J. A.,
Saxon S.,
Spelman D.,
Morrissey C. O.
Publication year - 2016
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12467
Subject(s) - colonisation , medicine , mucormycosis , retrospective cohort study , pediatrics , surgery , biology , colonization , microbiology and biotechnology
Summary Mucormycosis is associated with significant morbidity and mortality. We reviewed patients with mucormycete isolated at Alfred Health, Australia. A retrospective review of 66 patients with mucormycete(s) identified, between 1 April 2008 and 30 June 2014. Baseline demographic, microbiological, radiological, treatment/outcome data were recorded. Site of isolation was sinopulmonary in 77% and skin/soft tissue in 21%. A total of 32% of cases were proven‐ IFD , 12% probable‐ IFD and 56% were defined as no‐ IFD (or colonisation). Rhizopus spp. was identified in 48%. Comparing probable/proven‐ IFD with no‐ IFD /colonisation, more patients were postallogeneic stem cell transplantation (28% vs. 0%, P < 0.01) and were receiving immunosuppressive therapy (59% vs. 24%, P < 0.01) including prednisolone >20 mg daily (24% vs. 5%, P = 0.04). A total of 93% of patients with proven/probable IFD received treatment while 30% of no‐ IFD /colonisation were treated. A total of 72% of patients with proven/probable IFD and 92% of those with colonisation had no further mucormycete isolated. Thirty day mortality was higher in the proven/probable‐ IFD cohort (24%) compared with no‐ IFD /colonisation (3%) ( P = 0.02). Mucormycosis remains uncommon, with 56% of cases not associated with clinical infection. Immunosuppressive therapy remains strongly associated with mucormycosis. Mortality remains high in those with proven/probable IFD .